| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer
1 company
Greg Zante is Chief Financial Officer at VKTX. From January 2021 to July 2026, the filings on record show 0 open-market purchases and 12 sales. Greg Zante's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $5.5M at current prices.
Our model assigns Greg Zante a middling insider score of 55/100, based on 14 past trades. Over a 12-month horizon, 41.7% of those trades were profitable, with an average 12-month return of -35.5%.
The VKTX filings lean toward selling, a net 636,496 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 12, 2023 | VKTX Viking Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 97,839 | $18.00 | $1,761,310.29 | -39.6% | -9.8% | +299.7% | |
| Apr 3, 2023 | VKTX Viking Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 161,940 | $17.19 | $2,784,218.57 | -52.3% | -12.1% | +340.2% |